EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Increased Mitochondrial Superoxide Level Is Partially Associated With Vemurafenib‐Induced Renal Tubular Toxicity

Akimasa Sanagawa iD, Hiroshi Takase

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Akimasa Sanagawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Mitochondria, Superoxides, Vemurafenib, Kidney Tubules, Proximal. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public Foundation of Chubu Science and Technology Center, Aichi Cancer Research Foundation, JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vemurafenib (VEM) reportedly inhibits the mitochondrial respiratory chain and reduces ferrochelatase (FECH) activity, thereby causing VEM‐induced renal tubular toxicity. However, the exact mechanisms underlying VEM‐induced renal tubular toxicity remain unclear. In this study, we treated human renal proximal tubular epithelial cells with VEM to elucidate these mechanisms. VEM treatment for 24 h resulted in cell damage, reduced cell viability, increased lactate dehydrogenase release and elevated the production of inflammatory cytokines. Transmission electron microscopy (TEM) and fluorescence microscopy revealed accumulation and enlargement of lysosome‐derived vacuoles and mitochondrial superoxide production. Although MitoTracker showed no change in the total mitochondrial volume, TEM indicated mitochondrial damage, including smaller and less visible mitochondria. Enhanced superoxide production was confirmed using mtSOX. The mitochondria‐specific antioxidant XJB‐5‐131 partially alleviated VEM‐induced superoxide production and improved cell viability, indicating the role of superoxide in VEM‐induced renal tubular toxicity. The inhibition of lysosomal acidification by bafilomycin A1 did not mitigate VEM‐induced cytotoxicity, suggesting potential autophagy impairment. These findings highlight that mitochondrial dysfunction and lysosomal abnormalities are significant factors in VEM‐induced renal tubular toxicity, warranting further investigation into the relationship between their mechanisms, reduced FECH activity and potential renoprotective targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitochondriaSuperoxidesVemurafenibKidney Tubules, ProximalAntineoplastic AgentsHumansCell SurvivalCell LineLysosomesEpithelial CellsAutophagyCytokines

Stichwörter der Autor:innen

lysosomal abnormalitiesmitochondrial dysfunctionrenal tubular toxicitysuperoxidevemurafenib

Substanzen

SuperoxidesVemurafenibAntineoplastic AgentsCytokines

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Research Equipment Sharing Center, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Akimasa Sanagawa

Förderung

  • Public Foundation of Chubu Science and Technology Center
  • Aichi Cancer Research Foundation
  • JSPS
  • Japan Society for the Promotion of Science

Zitieren

APA

Sanagawa, A., & Takase, H. (2025). Increased Mitochondrial Superoxide Level Is Partially Associated With Vemurafenib‐Induced Renal Tubular Toxicity. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70015

Vancouver

Sanagawa A, Takase H. Increased Mitochondrial Superoxide Level Is Partially Associated With Vemurafenib‐Induced Renal Tubular Toxicity. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70015

BibTeX
@article{Sanagawa2025,
  author = {Sanagawa, Akimasa and Takase, Hiroshi},
  title = {Increased Mitochondrial Superoxide Level Is Partially Associated With Vemurafenib‐Induced Renal Tubular Toxicity},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70015}
}
Kostenlos starten →